Katherine Goodrich
CIK: 0002044770
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Tarsus Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
3.8K shares- - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
2.4K shares- - Jun 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3K shares at avg. $62.08$183K - Jun 12, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct3K shares- - Dec 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct2.2K shares- - Jun 12, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
3K shares- - Jun 12, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
4.5K shares- - Nov 13, 2024TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
10K shares- - Nov 13, 2024TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
6.7K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 3,837 | - | - | Direct |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 2,417 | - | - | Direct |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,954 | $62.08 | $183,384 | Direct |
| Jun 12, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 2,954 | - | $0 | Direct |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 2,233 | - | $0 | Direct |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 2,954 | - | - | Direct |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 4,540 | - | - | Direct |
| Nov 13, 2024 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 10,000 | - | - | Direct |
| Nov 13, 2024 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 6,700 | - | - | Direct |
1-9 of 9 transactions
About Goodrich Katherine
Goodrich Katherine (SEC CIK 0002044770) files insider reports with the SEC as Director of Tarsus Pharmaceuticals, Inc. (TARS).
Signal8 holds 7 ownership filings by Goodrich Katherine (1 Form 3, 6 Form 4), filed between Nov 15, 2024 and Jun 29, 2026. Those filings report 9 transactions, from Nov 13, 2024 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Goodrich Katherine's filings is in IRVINE, CA.
Recent filings by Goodrich Katherine
- Jun 25, 2026: Grants or awards of TARS derivative securities (2 lines, Form 4, code A).
- Jun 15, 2026: Open-market sale of TARS shares (Form 4, code S).
- Jun 12, 2026: Option exercise of TARS shares (Form 4, code M).
- Dec 15, 2025: Option exercise of TARS shares (Form 4, code M).
- Jun 12, 2025: Grants or awards of TARS derivative securities (2 lines, Form 4, code A).
Other insiders filing for Tarsus Pharmaceuticals, Inc. (TARS)
- PYOTT DAVID E I, Director
- YARNO WENDY L, Director
- LINK WILLIAM J PHD, Director
- Azamian Bobak R., President/CEO and Board Chair
- Lin Elizabeth Yeu, Chief Medical Officer
- Neervannan Seshadri, Chief Operating Officer